Abbott Reports Second-Quarter 2013 Results

                  Abbott Reports Second-Quarter 2013 Results

  PR Newswire

  ABBOTT PARK, Illinois, July 17, 2013

- Second-Quarter Ongoing EPS of $0.46, Above Previous Guidance Range (GAAP
EPS of $0.30) -

- Confirms Full-Year 2013 EPS Guidance, Representing Double-Digit Growth -

- Emerging Markets Operational Sales Increased More Than 13 Percent -

ABBOTT PARK, Illinois, July 17, 2013 /PRNewswire/ --Abbott (NYSE: ABT) today
announced financial results for the second quarter ended June 30, 2013.

  *Second-quarter adjusted diluted EPS was $0.46, above the previous guidance
    range; reported diluted EPS from continuing operations under GAAP was
    $0.30.
  *Abbott is confirming its full-year 2013 EPS guidance, representing
    double-digit growth.
  *Excluding foreign exchange, worldwide sales increased 4.2 percent.
    Reported sales increased 2.5 percent, including an unfavorable 1.7 percent
    effect of foreign exchange. Sales were driven by 8.4 percent operational
    sales growth in Nutrition, including 18.4 percent international growth,
    and 7.6 percent operational sales growth in Diagnostics.
  *Abbott continued to expand its presence in emerging markets across all
    business segments. Emerging market sales were $2.3 billion in the second
    quarter, an increase of 13.4 percent on an operational basis.
  *Second-quarter adjusted gross margin ratio of 55.0 percent exceeded
    previous expectations, driven by strong momentum in Nutrition and
    Diagnostics. The gross margin ratio under GAAP was 49.7 percent.
  *Abbott launched several new products and initiated new clinical trials in
    the second quarter. Highlights include 24 new product launches in
    Nutrition; the first FDA-approved hepatitis C virus (HCV) genotyping test;
    the initiation of a randomized clinical trial in Japan for Abbott's
    bioresorbable vascular scaffold, Absorb™; the approval of XIENCE
    Xpedition™ in Japan; and the U.S. approval and launch of the TECNIS® Toric
    1-Piece Intraocular Lens (IOL) for cataract patients with astigmatism.
  *On July 15, Abbott announced two acquisitions in its Medical Devices
    business: IDEV Technologies, which expands Abbott's endovascular
    portfolio, and OptiMedica, which provides an immediate entry point into
    the laser cataract surgery market.

"All things considered, including headwinds from foreign exchange and a mixed
global economy, this was a good quarter," said Miles D. White, chairman and
chief executive officer, Abbott.

Second-Quarter Business Overview

Following are the sales by business segment for the second quarter and first
half of the year, as well as commentary addressing second-quarter sales
performance:

Total Company

                                                      % Change vs. 2Q12
                    Sales ($ in
                  millions) 2Q13                    Int'l                  Total
                U.S.   Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total Sales *   1,560  3,886  5,446  (2.8)          7.2       4.8          4.2       2.5
Nutrition         714    990  1,704  (3.1)         18.4      17.4          8.4       7.9
Diagnostics       304    831  1,135    3.4          9.1       6.0          7.6       5.3
Established
Pharmaceuticals     -  1,218  1,218  n/a          0.2     (2.3)          0.2     (2.3)
Medical Devices   518    838  1,356  (5.7)          4.2       1.1          0.2     (1.6)
* Total Abbott Sales include Other sales of $33 million.

                                                       % Change vs. 1H12
                    Sales ($ in
                   millions) 1H13                    Int'l                  Total
                U.S.   Int'l  Total   U.S.   Operational  Reported  Operational  Reported
Total Sales *   3,094  7,730  10,824  (3.0)          6.8       4.4          3.8       2.1
Nutrition       1,433  1,971   3,404  (0.6)         16.6      15.8          8.7       8.3
Diagnostics       596  1,627   2,223    3.2          8.4       5.5          7.0       4.9
Established
Pharmaceuticals     -  2,450   2,450  n/a          0.7     (2.1)          0.7     (2.1)
Medical Devices 1,020  1,664   2,684  (9.3)          4.0       1.0        (1.4)     (3.1)
* Total Abbott Sales include Other sales of $63 million.
n/a = Not Applicable.
Note: Operational growth reflects percentage change over the prior year excluding the
impact of exchange rates.

Second-quarter 2013 worldwide sales of $5.4 billion increased 4.2 percent on
an operational basis, consistent with previous guidance, driven by 8.4 percent
operational sales growth in Nutrition, including 18.4 percent international
growth, and 7.6 percent operational sales growth in Diagnostics, including 9.1
percent international growth. On a reported basis, sales increased 2.5
percent, including an unfavorable 1.7 percent effect of foreign exchange.
Unfavorable exchange was primarily driven by the further weakening of the
Japanese yen versus the U.S. dollar.

Sales in emerging markets in the second quarter were $2.3 billion,
representing more than 40 percent of Abbott's total sales, increasing 13.4
percent on an operational basis and 12.7 percent on a reported basis.

Nutrition

                                                % Change vs. 2Q12
              Sales ($ in
             millions) 2Q13                   Int'l                  Total
           U.S.  Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total
Sales       714    990  1,704  (3.1)         18.4      17.4          8.4       7.9
Pediatric   376    585    961  (3.3)         19.4      19.9          9.3       9.6
Adult       338    405    743  (2.8)         17.1      14.1          7.2       5.7

                                                 % Change vs. 1H12
               Sales ($ in
             millions) 1H13                    Int'l                  Total
           U.S.   Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total
Sales      1,433  1,971  3,404  (0.6)         16.6      15.8          8.7       8.3
Pediatric    756  1,193  1,949  (0.5)         20.1      20.5         11.2      11.4
Adult        677    778  1,455  (0.7)         11.7       9.3          5.6       4.4

Worldwide Nutrition sales increased 8.4 percent in the second quarter on an
operational basis and 7.9 percent on a reported basis, including an
unfavorable 0.5 percent impact of foreign exchange.Total emerging market
sales, which represent more than 45 percent of total Nutrition sales,
increased strong double digits in the quarter. Abbott's broad and diverse
nutritional product portfolio is comprised of approximately 55 percent of
sales in Pediatric Nutrition and 45 percent of sales in Adult Nutrition.

Worldwide Pediatric Nutrition sales increased 9.3 percent on an operational
basis and 9.6 percent on a reported basis in the quarter, including a
favorable 0.3 percent impact of foreign exchange. International Pediatric
Nutrition sales grew 19.4 percent on an operational basis, driven by strong
performance in emerging markets as this business continues to execute on
geographic expansion initiatives and launch new product innovations.This
growth was partially offset by a modest decline in U.S. Pediatric Nutrition
largely driven by lower infant formula share in the WIC market segment.

Worldwide Adult Nutrition sales increased 7.2 percent on an operational basis
and 5.7 percent on a reported basis in the quarter, including an unfavorable
1.5 percent effect of foreign exchange. Sales growth in the quarter was led by
global growth of Ensure® and continued expansion of the adult nutrition market
where Abbott is the global leader. International Adult Nutrition sales grew
17.1 percent on an operational basis, driven by strong growth in emerging
markets.U.S. Adult Nutrition sales growth was negatively impacted by Abbott's
exit from certain non-core business lines as part of the division's margin
improvement initiative.

Nutrition operating margin improved significantly versus the second quarter of
2012 and is ahead of schedule to reach its initial target of 20 percent of
sales by 2015.

Abbott expects continued strong sales growth in worldwide Nutrition over the
course of the year, driven primarily by geographic expansion initiatives in
emerging markets and new product launches in both Pediatric and Adult
Nutrition.

Diagnostics

                                                % Change vs. 2Q12
              Sales ($ in
             millions) 2Q13                   Int'l                  Total
           U.S.  Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total
Sales       304    831  1,135    3.4          9.1       6.0          7.6       5.3
Core
Laboratory  171    744    915  (2.6)          8.3       5.0          6.1       3.5
Molecular    52     67    119    7.4         17.7      15.5         13.0      11.8
Point of
Care         81     20    101   15.5         15.2      14.8         15.5      15.4

                                                % Change vs. 1H12
              Sales ($ in
             millions) 1H13                   Int'l                  Total
           U.S.  Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total
Sales       596  1,627  2,223    3.2          8.4       5.5          7.0       4.9
Core
Laboratory  334  1,464  1,798  (4.1)          8.6       5.5          6.1       3.6
Molecular   100    125    225    4.7          9.7       7.6          7.5       6.3
Point of
Care        162     38    200   20.9          0.5       0.2         16.4      16.3

Worldwide Diagnostics sales increased 7.6 percent in the second quarter on an
operational basis, including strong double-digit growth in Molecular and Point
of Care Diagnostics. Reported sales increased 5.3 percent, including an
unfavorable 2.3 percent effect of foreign exchange.

Core Laboratory Diagnostics sales increased 6.1 percent on an operational
basis. Reported sales in Core Laboratory Diagnostics increased 3.5 percent,
including an unfavorable 2.6 percent of foreign exchange. Operational sales
growth was driven by 8.3 percent growth in international sales, driven by
continued strong performance in key emerging markets, with sales in China and
Russia growing more than 30 percent.

Molecular Diagnostics sales increased 13.0 percent on an operational basis, in
line with expectations for accelerated growth. Reported worldwide Molecular
sales increased 11.8 percent, including an unfavorable 1.2 percent effect of
foreign exchange. Sales were driven by strong infectious disease growth,
particularly in emerging markets due to the impact of new tenders, as well as
the continued global expansion of the anaplastic lymphoma kinase (ALK) gene
test for non-small-cell lung cancer. In June, Abbott received approval for the
first FDA-approved hepatitis C virus (HCV) genotyping test in the U.S., which
will enable physicians to create a personalized, targeted diagnosis and
treatment path to improve clinical outcomes. This test will further expand
Abbott's diagnostic testing options in infectious disease.

Point of Care Diagnostics also contributed to strong sales growth, increasing
15.5 percent on an operational basis and 15.4 percent on reported basis,
reflecting minimal impact of foreign exchange. Abbott holds the leadership
position in the U.S., where sales increased 15.5 percent driven by continued
growth in the U.S. hospital segment and further penetration in physician
office labs.

Abbott is continuing the development of six new system platforms across Core
Laboratory, Molecular and Point of Care Diagnostics that are designed to
improve service to our customers, enhance laboratory productivity, improve
efficiency and reduce costs.

Established Pharmaceuticals

                                             % Change vs. 2Q12
            Sales ($ in
           millions) 2Q13                  Int'l                  Total
         U.S.  Int'l  Total  U.S.  Operational  Reported  Operational  Reported
Total
Sales       -  1,218  1,218   n/a          0.2     (2.3)          0.2     (2.3)
Key
Emerging
Markets     -    590    590   n/a          4.4       2.5          4.4       2.5
Other
Markets     -    628    628   n/a        (3.4)     (6.4)        (3.4)     (6.4)

                                             % Change vs. 1H12
            Sales ($ in
           millions) 1H13                  Int'l                  Total
         U.S.  Int'l  Total  U.S.  Operational  Reported  Operational  Reported
Total
Sales       -  2,450  2,450   n/a          0.7     (2.1)          0.7     (2.1)
Key
Emerging
Markets     -  1,175  1,175   n/a          6.5       3.4          6.5       3.4
Other
Markets     -  1,275  1,275   n/a        (4.0)     (6.7)        (4.0)     (6.7)
n/a = Not Applicable.

Established Pharmaceuticals sales increased 0.2 percent in the second quarter
on an operational basis and decreased 2.3 percent on a reported basis,
including an unfavorable 2.5 percent effect of foreign exchange.

Abbott is focused on expanding its presence and building local product
portfolios in 14 Key Emerging Markets where access to quality healthcare is
expanding. Sales in these Key Emerging Markets increased 4.4 percent on an
operational basis and 2.5 percent on a reported basis in the quarter,
including an unfavorable 1.9 percent effect of foreign exchange.

Other Markets include developed markets, such as Western Europe and Japan, and
other emerging markets globally. Sales in these geographies decreased 3.4
percent on an operational basis and 6.4 percent on a reported basis in the
quarter, including an unfavorable 3.0 percent effect of foreign exchange. As
expected, sales growth in developed markets continues to be negatively
impacted by macroeconomic conditions, including European austerity measures.

Abbott expects Established Pharmaceuticals operational sales growth to improve
over the course of the year, primarily driven by continued strong performance
in Russia, along with acceleration of growth in India and Brazil due to
portfolio expansion and execution of recent tender wins.

Medical Devices

                                                      % Change vs. 2Q12
                    Sales ($ in
                   millions) 2Q13                   Int'l                  Total
                 U.S.  Int'l  Total  U.S.   Operational  Reported  Operational  Reported
Total Sales       518    838  1,356  (5.7)          4.2       1.1          0.2     (1.6)
Vascular          286    464    750  (6.8)          4.4       1.3        (0.1)     (2.0)
Diabetes Care     135    191    326  (6.8)          4.1       3.0        (0.7)     (1.3)
Medical Optics     97    183    280  (0.8)          3.7     (1.4)          2.2     (1.2)
Vascular
Product Lines:
DES/BVS(a)        128    261    389  (8.7)          5.3       0.5          0.4     (2.7)
Other Coronary
Products(b)        50     96    146    0.9        (0.3)     (1.6)          0.1     (0.8)
Endovascular(c)    62     57    119    3.2          4.6       4.9          3.8       4.0

                                                       % Change vs. 1H12
                     Sales ($ in
                   millions) 1H13                     Int'l                  Total
                 U.S.   Int'l  Total   U.S.   Operational  Reported  Operational  Reported
Total Sales      1,020  1,664  2,684   (9.3)          4.0       1.0        (1.4)     (3.1)
Vascular           562    930  1,492  (13.4)          4.1       1.1        (3.1)     (4.9)
Diabetes Care      268    374    642   (5.3)          3.7       2.5        (0.2)     (0.9)
Medical Optics     190    360    550   (1.3)          3.8     (0.6)          2.0     (0.9)
Vascular
Product Lines:
DES/BVS(a)         254    522    776  (12.1)          6.0       1.6        (0.5)     (3.4)
Other Coronary
Products(b)         96    196    292   (3.9)        (1.4)     (2.9)        (2.2)     (3.2)
Endovascular(c)    121    113    234   (0.5)          5.9       5.7          2.5       2.4
(a)Includes drug-eluting stents and bioresorbable vascular scaffold
(BVS) product portfolio.
(b)Includes guide wires, balloon catheters and other
coronary products.
(c)Includes vessel closure, carotid stents and other
peripheral products.

Worldwide Medical Devices sales increased 0.2 percent in the second quarter on
an operational basis. Reported sales decreased 1.6 percent, including an
unfavorable 1.8 percent effect of foreign exchange.

Worldwide Vascular sales were flat on an operational basis, consistent with
previous guidance. Reported sales decreased 2.0 percent, including an
unfavorable 1.9 percent effect of foreign exchange. International Vascular
sales comprise more than 60 percent of total Vascular sales and increased 4.4
percent operationally, driven by new product introductions, including recent
international launches of XIENCE Xpedition, Abbott's new drug-eluting stent,
and Absorb, the world's first coronary bioresorbable vascular scaffold (BVS),
as well as the XIENCE PRIME™ small vessel launch in Japan. Sales increases in
Endovascular and MitraClip®, Abbott's first-in-class device for the treatment
of mitral regurgitation, also contributed to international sales growth in the
quarter. U.S. Vascular sales were impacted by pricing pressure and a decline
in procedures due to market conditions, partially offset by a year-over-year
increase in market share as a result of XIENCE Xpedition launch. The overall
Vascular sales growth rate in the second quarter improved when compared to the
first-quarter 2013 growth rate.

Abbott expects worldwide sales growth to improve over the course of the year,
with the continued uptake of XIENCE Xpedition in the U.S., the launch of
XIENCE Xpedition in Japan, which was announced last week, and continued
international penetration of new products, MitraClip and Absorb. On July 15,
Abbott announced the acquisition of IDEV Technologies, which complements
Abbott's existing portfolio of endovascular products with a best-in-class
technology, designed to treat patients with peripheral artery disease.Abbott
expects to complete the acquisition before the end of 2013.

Worldwide Diabetes Care sales decreased 0.7 percent on an operational basis,
consistent with previous guidance. Reported sales decreased 1.3 percent,
including an unfavorable 0.6 percent effect of foreign exchange. Outside of
the U.S., sales growth was driven by continued uptake of our FreeStyle
InsuLinx® meter and share gains in emerging markets, including Saudi Arabia,
where Abbott was recently selected as the exclusive supplier for the National
Diabetes Awareness Program. As expected, U.S. sales were impacted by market
pricing and reimbursement pressures, partially offset by continued share gains
in the hospital and retail segments, where Abbott maintains a leadership
position. Abbott continues to invest in a next-generation sensing technology
that is expected to be initially launched in the European market in the second
half of 2014.

Worldwide Medical Optics sales increased 2.2 percent on an operational basis,
consistent with previous guidance. Reported sales declined 1.2 percent,
including an unfavorable 3.4 percent effect of foreign exchange. Cataract
sales, which represent 60 percent of total Medical Optics sales, increased
high-single digits, outpacing the market, including continued double-digit
growth in emerging markets. This growth was partially offset by a decline in
refractive sales driven by continued soft market conditions. Abbott expects
Medical Optics performance to improve in the second half of the year driven by
new product introductions in the cataract segment, including the recent launch
of TECNIS OptiBlue® IOL in Japan, which provides Abbott access to the largest
segment of the Japan market, and TECNIS Toric IOL in the U.S. for patients
with astigmatism, which enables Abbott to compete in the fastest-growing
premium segment of the IOL market. The expected launch of TECNIS Preloaded IOL
in the U.S. also will contribute to growth over the course of the year. On
July 15, Abbott announced the acquisition of OptiMedica, which will allow
Abbott to expand its vision care business into the rapidly developing
laser-assisted cataract surgery market. Abbott expects to complete the
acquisition before the end of 2013.

Abbott confirms full-year 2013 guidance

Abbott is confirming ongoing earnings-per-share guidance for the full year
2013 of $1.98 to $2.04. Abbott forecasts net specified items for the full year
2013 of approximately $0.59 per share. Including these net specified items,
projected earnings per share from continuing operations under Generally
Accepted Accounting Principles (GAAP) would be $1.39 to $1.45 for the full
year 2013. Specified items are primarily associated with intangible
amortization expense, cost reduction initiatives, and the impact in the first
quarter of the favorable effect of U.S. tax law changes enacted in 2013
related to 2012 results.

Abbott declares 358th quarterly dividend and $3 billion share repurchase
program

On June 14, 2013, the board of directors of Abbott declared the company's
quarterly common dividend of $0.14 per share. Abbott's cash dividend is
payable Aug. 15, 2013, to shareholders of record at the close of business on
July 15, 2013. The board of directors also authorized the repurchase of up to
$3 billion of Abbott's common shares, as market conditions warrant and subject
to regulatory considerations.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life
through the development of products and technologies that span the breadth of
healthcare. With a portfolio of leading, science-based offerings in
diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals, Abbott serves people in more than 150 countries and employs
approximately 70,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Abbott will webcast its live second-quarter earnings conference call through
its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central
time today. An archived edition of the call will be available after 11 a.m.
Central time.

— Private Securities Litigation Reform Act of 1995 — A Caution Concerning
Forward-Looking Statements

Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995. Abbott
cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect Abbott's
operations are discussed in Item 1A, "Risk Factors,'' to our Annual Report on
Securities and Exchange Commission Form 10-K/A for the year ended Dec. 31,
2012, and are incorporated by reference. Abbott undertakes no obligation to
release publicly any revisions to forward-looking statements as a result of
subsequent events or developments, except as required by law.

                    Abbott Laboratories and Subsidiaries

                     Consolidated Statement of Earnings

                 Second Quarter Ended June 30, 2013 and 2012

                    (in millions, except per share data)

                                 (unaudited)
                                        2Q13        2Q12       % Change
Net Sales                               $5,446      $5,313           2.5
Cost of products sold, excluding
amortization expense                     2,545       2,370           7.4
Amortization of intangible assets          197         195           1.0
Research and development                   363         370         (2.2)
Selling, general, and
administrative                           1,714       1,814         (5.5)
Total Operating Cost and Expenses        4,819       4,749           1.5
Operating earnings                         627         564          11.2
Net interest expense                        23          64        (63.3)
Net foreign exchange (gain) loss            11        (25)           n/m
Other (income) expense, net                (8)         (5)           n/m
Earnings from Continuing
Operations before taxes                    601         530          13.5
Taxes on Earnings from Continuing
Operations                                 125         119           5.1
Net Earnings from Continuing
Operations                                 476         411          15.9
Earnings from Discontinued
Operations, net of taxes                    --       1,314           n/m
Net Earnings                              $476      $1,725        (72.4)
Net Earnings from Continuing
Operations Excluding                     $724        $689           5.2   1)
Specified Items, as described
below
Diluted Earnings per Common Share
from Continuing Operations               $0.30       $0.26          15.4
Diluted Earnings per Common Share
from Discontinued Operations                --       $0.82           n/m
Diluted Earnings per Common
Share                                   $0.30       $1.08        (72.2)
Diluted Earnings per Common Share
from Continuing                         $0.46       $0.43           7.0   1)
Operations, Excluding Specified
Items, as described below
Average Number of Common Shares
Outstanding                              1,577       1,589
Plus Dilutive Common Stock
Options and Awards
1) 2013 Net Earnings from Continuing Operations Excluding Specified Items
excludes after-tax charges of $248 million, or $0.16 per share, for
intangible amortization expense, cost reduction initiatives and other costs.
2012 Net Earnings from Continuing Operations Excluding Specified Items
excludes after-tax charges of $278 million, or $0.17 per share, for
intangible amortization expense, specified items previously identified in
Abbott's earnings release dated July 18, 2012, related to Abbott's continuing
operations, certain costs that transferred or will be charged to AbbVie, and
an interest expense adjustment to reflect Abbott's capital structure after
the separation of AbbVie, as detailed in the 8-K dated April 16, 2013.
NOTES:
a) See tablesbelow for an explanation of certain non-GAAP financial
information.
b) "Discontinued Operations" reflect the operations of the AbbVie business,
which became an independent company onJan.1, 2013.
n/m = Percent change is not meaningful.

                    Abbott Laboratories and Subsidiaries

                     Consolidated Statement of Earnings

                   First Half Ended June 30, 2013 and 2012

                    (in millions, except per share data)

                                 (unaudited)
                                              1H13       1H12     % Change
Net Sales                                     $10,824   $10,597        2.1
Cost of products sold, excluding
amortization expense                            4,977     4,729        5.2
Amortization of intangible assets                 396       404      (2.0)
Research and development                          709       734      (3.5)
Selling, general, and administrative            3,500     3,656      (4.3)
Total Operating Cost and Expenses               9,582     9,523        0.6
Operating earnings                              1,242     1,074       15.7
Net interest expense                               49       130     (62.1)
Net foreign exchange (gain) loss                   40      (10)        n/m
Other (income) expense, net                       (2)      (39)        n/m
Earnings from Continuing Operations
before taxes                                    1,155       993       16.4
Taxes on Earnings from Continuing
Operations                                        134       231     (41.7) 1)
Net Earnings from Continuing Operations         1,021       762       33.9
Earnings from Discontinued Operations,
net of taxes                                       --     2,205        n/m
Net Earnings                                   $1,021    $2,967     (65.4)
Net Earnings from Continuing Operations
Excluding                                     $1,399    $1,334        4.9 2)
Specified Items, as described below
Diluted Earnings per Common Share from
Continuing Operations                           $0.64     $0.47       36.2
Diluted Earnings per Common Share from
Discontinued Operations                            --     $1.38        n/m
Diluted Earnings per Common Share              $0.64     $1.85     (65.4)
Diluted Earnings per Common Share from
Continuing                                     $0.88     $0.83        6.0 2)
Operations, Excluding Specified Items, as
described below
Average Number of Common Shares
Outstanding                                     1,582     1,589
Plus Dilutive Common Stock Options and
Awards
1) 2013 Taxes on Earnings from Continuing Operations include a favorable
adjustment to tax expense of $103 million, or $0.07 per share, for the impact
in the first quarter of U.S. tax law changes enacted in 2013 related to 2012
results. This favorable item has been classified as a specified item and
excluded from ongoing results, as discussed below.
2) 2013 Net Earnings from Continuing Operations Excluding Specified Items
excludes after-tax charges of $481 million, or $0.31 per share, for
intangible amortization expense, cost reduction initiatives and other costs.
These items were partially offset by the favorable adjustment to tax expense
of $103 million, or $0.07 per share, for the impact in the first quarter of
U.S. tax law changes enacted in 2013 related to 2012 results.
2012 Net Earnings from Continuing Operations Excluding Specified Items
excludes after-tax charges of $572 million, or $0.36 per share, for
intangible amortization expense, specified items previously identified in
Abbott's earnings release dated July 18, 2012, related to Abbott's continuing
operations, certain costs that transferred or will be charged to AbbVie, and
an interest expense adjustment to reflect Abbott's capital structure after
the separation of AbbVie, as detailed in the 8-K dated April 16, 2013.
NOTES:
c) See tablesbelow for an explanation of certain non-GAAP financial
information.
d) "Discontinued Operations" reflect the operations of the AbbVie business,
which became an independent company on Jan.1, 2013.
n/m = Percent change is not meaningful.

Non-GAAP Reconciliation of Financial Information
                    Abbott Laboratories and Subsidiaries

              Non-GAAP Reconciliation of Financial Information

                 Second Quarter Ended June 30, 2013 and 2012

                    (in millions, except per share data)

                                 (unaudited)
                                                      2Q13
                                   As reported  Specified               % to
                                     (GAAP)       Items    As Adjusted  Sales
Intangible Amortization Expense           $197     ($197)           --
Gross Margin                            $2,704       $291       $2,995  55.0%
R&D                                       $363       ($8)         $355   6.5%
SG&A                                    $1,714      ($17)       $1,697  31.2%
Earnings from Continuing
Operations before taxes                  $601       $316         $917
Net Earnings from Continuing
Operations                                $476       $248         $724
Diluted Earnings per Share from
Continuing Operations                    $0.30      $0.16        $0.46

Specified items reflect intangible amortization expense of $197 million and
cost reduction initiatives and other costs of $119 million.

                                                      2Q12
                                   As reported  Specified               % to
                                     (GAAP)       Items    As Adjusted  Sales
Intangible Amortization Expense           $195     ($195)           --
Gross Margin                            $2,748       $220       $2,968  55.9%
R&D                                       $370       ($3)         $367   6.9%
SG&A                                    $1,814     ($120)       $1,694  31.9%
Net Interest Expense                       $64      ($34)          $30
Earnings from Continuing
Operations before taxes                   $530       $377         $907
Net Earnings from Continuing
Operations                                $411       $278         $689
Diluted Earnings per Share from
Continuing Operations                    $0.26      $0.17        $0.43

Specified items include intangible amortization expense of $195 million; $148
million for specified items previously identified in Abbott's earnings release
dated July 18, 2012, related to Abbott's continuing operations, the removal of
certain corporate costs that transferred to AbbVie in the separation and
certain costs that will be charged to AbbVie under transition service
agreements; and $34 million for an adjustment to interest expense to reflect
Abbott's capital structure after the separation of AbbVie, as detailed in the
8-K dated April 16, 2013.

                    Abbott Laboratories and Subsidiaries

              Non-GAAP Reconciliation of Financial Information

                   First Half Ended June 30, 2013 and 2012

                    (in millions, except per share data)

                                 (unaudited)
                                                    1H13
                                                                        % to
                                  As       Specified Items              Sales
                               reported  Tax Expense             As
                                (GAAP)   Adjustment   Other   Adjusted
Intangible Amortization
Expense                            $396           --  ($396)        --
Gross Margin                     $5,451           --    $544    $5,995  55.4%
R&D                                $709           --    ($5)      $704   6.5%
SG&A                             $3,500           --   ($48)    $3,452  31.9%
Net Foreign Exchange
(Gain)/Loss                         $40           --   ($15)       $25
Other (Income)/Expense             ($2)           --    ($3)      ($5)
Earnings from Continuing
Operations before taxes         $1,155           --    $615    $1,770
Net Earnings from Continuing
Operations                       $1,021       ($103)    $481    $1,399
Diluted Earnings per Share
from Continuing Operations        $0.64      ($0.07)   $0.31     $0.88

Tax Expense Adjustment is the tax benefit recorded in the first quarter for
the impact of U.S. tax law changes enacted in 2013 related to 2012 results.
Other specified items reflect intangible amortization expense of $396 million
and cost reduction initiatives and other costs of $219 million.

                                                      1H12
                                   As reported  Specified               % to
                                     (GAAP)       Items    As Adjusted  Sales
Intangible Amortization Expense           $404     ($404)           --
Gross Margin                            $5,464       $457       $5,921  55.9%
R&D                                       $734       ($2)         $732   6.9%
SG&A                                    $3,656     ($246)       $3,410  32.2%
Net Interest Expense                      $130      ($72)          $58
Earnings from Continuing
Operations before taxes                   $993       $777       $1,770
Net Earnings from Continuing
Operations                                $762       $572       $1,334
Diluted Earnings per Share from
Continuing Operations                    $0.47      $0.36        $0.83

Specified items include intangible amortization expense of $404 million; $301
million for specified items previously identified in Abbott's earnings release
dated July 18, 2012, related to Abbott's continuing operations, the removal of
certain corporate costs that transferred to AbbVie in the separation and
certain costs that will be charged to AbbVie under transition service
agreements; and $72 million for an adjustment to interest expense to reflect
Abbott's capital structure after the separation of AbbVie, as detailed in the
8-K dated April 16, 2013.

Tax Rate Reconciliation
                                                2Q13
(dollars in millions)      Pre-Tax Income 1)  Taxes on Earnings  Tax Rate
As reported (GAAP)                       601                125     20.8%
Specified Items                          316                 68     21.5%
Excluding specified items                917                193     21.0%
                                                2Q12
(dollars in millions)      Pre-Tax Income 1)  Taxes on Earnings  Tax Rate
As reported (GAAP)                       530                119     22.4%
Specified Items                          377                 99     26.3%
Excluding specified items                907                218     24.0%
1) Pre-Tax Income from Continuing Operations.

                                             1H13
(dollars in                                      Taxes on
millions)              Pre-Tax Income 2)         Earnings     Tax Rate
As reported (GAAP)                  1,155              134         11.6%
Specified Items                       615              237         38.6%   3)
Excluding specified
items                               1,770              371         21.0%
                                             1H12
(dollars in                                      Taxes on
millions)              Pre-Tax Income 2)         Earnings     Tax Rate
As reported (GAAP)                    993              231         23.2%
Specified Items                       777              205         26.4%
Excluding specified
items                               1,770              436         24.6%
2) Pre-Tax Income from Continuing Operations.
3) Specified Items include a favorable adjustment to tax expense of $103
million for the impact in the first quarter of U.S. tax law changes enacted
in 2013 related to 2012 results.

Website: http://www.abbott.com
Contact: Financial, Brian Yoor, +1-847-937-6343, or Tina Ventura,
+1-847-935-9390, or Scott Leinenweber, +1-847-935-1898; or Media, Scott
Stoffel, +1-847-936-9502, or Angela Duff, +1-847-938-6894
 
Press spacebar to pause and continue. Press esc to stop.